Disclosed are an aqueous UV curable ink and the method of preparing the same. In particular, the disclosure relates to a UV curable aqueous dispersant and a method of preparing the same; a UV curable aqueous ink composition and a method of preparing the same; and a method of forming an image on a recording medium. The UV curable aqueous dispersant according to the disclosure, and the UV curable aqueous ink composition including the same have no limitations in selecting a material, and improve the texture and fastness of an object, which is subjected to printing, in the fields of textile.

Disclosed are an aqueous UV curable ink and the method of preparing the same. In particular, the disclosure relates to a UV curable aqueous dispersant and a method of preparing the same; a UV curable aqueous ink composition and a method of preparing the same; and a method of forming an image on a recording medium. The UV curable aqueous dispersant according to the disclosure, and the UV curable aqueous ink composition including the same have no limitations in selecting a material, and improve the texture and fastness of an object, which is subjected to printing, in the fields of textile.

Metallo supramolecular polymer conetworks (MSMC) of poly[r(alkyl).sub.a-N-(pyridin-s-yl) (meth)-acrylamide moiety].sub.m,n derivatives-complexed to a transition metal cation-linked by poly(dimethylsiloxane).sub.palkyl-(meth)-acrylate moiety derivatives, wherein a is 0 or 1 or 2, p is an integer selected from the group consisting of from 50 to 70 and of from 120 to 180, r is integer of from 0 to 4, and s is an integer of from 2 to 4, and m and n, independently, are integers of from 5 to 11. These MSMC can be used as film or coating on a substrate and are exhibiting self-healing and bacterial anti-adhesion properties.

Metallo supramolecular polymer conetworks (MSMC) of poly[r(alkyl).sub.a-N-(pyridin-s-yl) (meth)-acrylamide moiety].sub.m,n derivatives-complexed to a transition metal cation-linked by poly(dimethylsiloxane).sub.palkyl-(meth)-acrylate moiety derivatives, wherein a is 0 or 1 or 2, p is an integer selected from the group consisting of from 50 to 70 and of from 120 to 180, r is integer of from 0 to 4, and s is an integer of from 2 to 4, and m and n, independently, are integers of from 5 to 11. These MSMC can be used as film or coating on a substrate and are exhibiting self-healing and bacterial anti-adhesion properties.

An aqueous ink composition for inkjet printing on non-porous substrates and a method for forming the same are disclosed. For example, the method includes preparing a primary polymer latex with an aromatic functional group, a hydrogen-bonding group, a flexible side-chain, and an ionic functional group and mixing the primary polymer latex with a secondary latex binder and one or more co-solvents.

An aqueous ink composition for inkjet printing on non-porous substrates and a method for forming the same are disclosed. For example, the method includes preparing a primary polymer latex with an aromatic functional group, a hydrogen-bonding group, a flexible side-chain, and an ionic functional group and mixing the primary polymer latex with a secondary latex binder and one or more co-solvents.

One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.

One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.

The present invention provides a maleimide-based copolymer, a method for producing same, and a resin composition obtained using same.

This maleimide-based copolymer contains 40-60 mass % of aromatic vinyl monomer units, 5-20 mass % of vinyl cyanide monomer units, and 35-50 mass % of maleimide monomer units, and is such that a 4 mass % tetrahydrofuran solution of the copolymer has a transmittance of 90% or more for light having a wavelength of 450 nm at an optical path length of 10 mm, and the residual maleimide-based monomer amount is less than 300 ppm. This maleimide-based copolymer preferably further contains 0-10 mass % of unsaturated dicarboxylic acid anhydride monomer units, and preferably has a glass transition temperature of 165° C. or higher.

The present invention provides a maleimide-based copolymer, a method for producing same, and a resin composition obtained using same.

This maleimide-based copolymer contains 40-60 mass % of aromatic vinyl monomer units, 5-20 mass % of vinyl cyanide monomer units, and 35-50 mass % of maleimide monomer units, and is such that a 4 mass % tetrahydrofuran solution of the copolymer has a transmittance of 90% or more for light having a wavelength of 450 nm at an optical path length of 10 mm, and the residual maleimide-based monomer amount is less than 300 ppm. This maleimide-based copolymer preferably further contains 0-10 mass % of unsaturated dicarboxylic acid anhydride monomer units, and preferably has a glass transition temperature of 165° C. or higher.